Epicrispr Biotechnologies

Epicrispr Biotechnologies raised a $90M Series C round co-led by Octagon Capital and Janus Henderson to advance epigenetic-editing treatments for FSHD (facioscapulohumeral muscular dystrophy), expand its pipeline, and scale the company.